ScPharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
150
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$421M
ScPharmaceuticals General Information
Description
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Contact Information
Website
www.scpharmaceuticals.com(Operating Subsidiary)
Corporate Office
- 25 Mall Road
- Suite 203
- Burlington, MA 01803
- United States
Corporate Office
- 25 Mall Road
- Suite 203
- Burlington, MA 01803
- United States
ScPharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 07-Oct-2025 | $421M | Completed | Generating Revenue | ||
| 8. 2PO | 13-Aug-2024 | Completed | Generating Revenue | |||
| 7. Debt Refinancing | 12-Aug-2024 | Completed | Generating Revenue | |||
| 6. General Corporate Purpose | 11-Oct-2022 | Completed | Generating Revenue | |||
| 5. 2PO | 22-May-2020 | Completed | Generating Revenue | |||
| 4. IPO | 17-Nov-2017 | Completed | Generating Revenue | |||
| 3. Debt - General | 23-May-2017 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 23-Dec-2016 | $45.6M | $69.8M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 15-Jun-2016 | $24.2M | $24.2M | Completed | Generating Revenue |
ScPharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
ScPharmaceuticals Comparisons
Industry
Financing
Details
ScPharmaceuticals Competitors (5)
One of ScPharmaceuticals’s 5 competitors is SQ Innovation, a Venture Capital-Backed company based in Burlington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SQ Innovation | Venture Capital-Backed | Burlington, MA | ||||
| Insulet | Formerly VC-backed | Acton, MA | ||||
| Tenaya Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Owen Mumford | Corporate Backed or Acquired | Chipping Norton, United Kingdom | ||||
| Haselmeier | Private Equity-Backed | Stuttgart, Germany |
ScPharmaceuticals Patents
ScPharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026152113-A1 | Furosemide formulations | Pending | 13-Jan-2025 | ||
| AU-2024207876-A1 | Methods of treatment using loop diuretics | Pending | 09-Jan-2023 | ||
| EP-4648761-A1 | Methods of treatment using loop diuretics | Pending | 09-Jan-2023 | ||
| US-20260232621-A1 | Methods of treatment using loop diuretics | Pending | 09-Jan-2023 | ||
| WO-2024151502-A1 | Methods of treatment using loop diuretics | Inactive | 09-Jan-2023 | A61P7/06 |
ScPharmaceuticals Signals
ScPharmaceuticals Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5AM Ventures | Venture Capital | Minority | ||
| Gilde Healthcare | PE/Buyout | Minority | ||
| Lundbeckfonden BioCapital | Venture Capital | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Sun Pharmaceutical Industries | Corporation | Minority |
ScPharmaceuticals ESG
Risk Overview
Risk Rating
Updated June, 30, 2025
39.13 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
ScPharmaceuticals FAQs
-
When was ScPharmaceuticals founded?
ScPharmaceuticals was founded in 2013.
-
Where is ScPharmaceuticals headquartered?
ScPharmaceuticals is headquartered in Burlington, MA.
-
What is the size of ScPharmaceuticals?
ScPharmaceuticals has 150 total employees.
-
What industry is ScPharmaceuticals in?
ScPharmaceuticals’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is ScPharmaceuticals a private or public company?
ScPharmaceuticals is a Private company.
-
What is the current valuation of ScPharmaceuticals?
The current valuation of ScPharmaceuticals is .
-
What is ScPharmaceuticals’s current revenue?
The current revenue for ScPharmaceuticals is .
-
How much funding has ScPharmaceuticals raised over time?
ScPharmaceuticals has raised $487M.
-
Who are ScPharmaceuticals’s investors?
5AM Ventures, Gilde Healthcare, Lundbeckfonden BioCapital, OrbiMed, and Sun Pharmaceutical Industries have invested in ScPharmaceuticals.
-
Who are ScPharmaceuticals’s competitors?
SQ Innovation, Insulet, Tenaya Therapeutics, Owen Mumford, and Haselmeier are competitors of ScPharmaceuticals.
-
When was ScPharmaceuticals acquired?
ScPharmaceuticals was acquired on 07-Oct-2025.
-
Who acquired ScPharmaceuticals?
ScPharmaceuticals was acquired by MannKind.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process